Takazono, Takahiro
Fujita, Satoki
Komeda, Takuji
Miyazawa, Shogo
Yoshida, Yuki
Kitanishi, Yoshitake
Kinoshita, Masahiro
Kojima, Satoshi
Shen, Huilian
Uehara, Takeki
Hosogaya, Naoki
Iwanaga, Naoki
Mukae, Hiroshi
Article History
Received: 22 August 2024
Accepted: 12 September 2024
First Online: 27 September 2024
Declarations
:
: Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, Masahiro Kinoshita, Satoshi Kojima, Huilian Shen, and Takeki Uehara are employees of Shionogi & Co., Ltd. and may hold stocks in the company. Takahiro Takazono has received personal fees from Shionogi & Co., Ltd., MSD K.K., Pfizer Japan Inc., Insmed GK., Asahi Kasei Pharma Corporation, and Kyorin Pharmaceutical Co., Ltd. Hiroshi Mukae has also received personal fees from AbbVie GK., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., FUJIFILM Toyama Chemical Co., Ltd., Gilead Sciences Inc., Insmed GK., Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Nihon Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Sumitomo Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Taisho Pharma Co., Ltd., Teijin Healthcare Ltd., and Toa Shinyaku Co., Ltd., and grants from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., FUJIFILM Toyama Chemical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Toa Shinyaku Co., Ltd., and Torii Pharmaceutical Co., Ltd., outside the submitted work. Naoki Hosogaya and Naoki Iwanaga have no conflicts of interest to disclose.
: The analysis included in this letter is based on the original study and does not contain any new studies with human participants or animals performed by any of the authors. The original study was conducted according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects. It used anonymized information from an existing database, and informed consent was therefore not required. This study was registered in UMIN Clinical Trials Registry (study ID: UMIN000053217).
: We thank Tomoko Tsushima and Tsukasa Horiyama in Shionogi & Co., Ltd. for Medical Writing/Editorial Assistance.